Sarepta Therapeutics, Inc. - Laporan Laba Rugi (TTM)

Sarepta Therapeutics, Inc.
US ˙ NasdaqGS ˙ US8036071004

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Sarepta Therapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 495 540 573 600 646 702 766 835 876 933 976 1,003 1,105 1,243 1,403 1,505 1,640 1,902 2,233 2,482
Change (%) 9.09 6.16 4.66 7.58 8.72 9.10 9.06 4.89 6.50 4.57 2.84 10.12 12.52 12.87 7.25 8.99 15.95 17.42 11.11
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 795 786 854 912 869 862 876 907 1,001 1,017 1,072 1,058 1,033 1,028 998 946 1,031 1,124 1,784 1,916
Change (%) -1.13 8.75 6.70 -4.71 -0.76 1.60 3.54 10.38 1.60 5.41 -1.32 -2.39 -0.48 -2.89 -5.19 8.97 8.98 58.74 7.44
% of Revenue 160.50 145.46 149.01 151.92 134.57 122.83 114.38 108.59 114.27 109.01 109.88 105.44 93.45 82.66 71.12 62.87 62.86 59.08 79.86 77.23
Gross Operating Profit -300 -246 -281 -312 -223 -160 -110 -72 -125 -84 -96 -55 72 216 405 559 609 778 450 565
Change (%) -18.03 14.45 10.87 -28.37 -28.20 -31.27 -34.87 74.22 -32.73 14.67 -43.42 -232.65 198.04 87.99 37.87 9.04 27.75 -42.23 25.67
% of Revenue -60.50 -45.46 -49.01 -51.92 -34.57 -22.83 -14.38 -8.59 -14.27 -9.01 -9.88 -5.44 6.55 17.34 28.88 37.13 37.14 40.92 20.14 22.77
SG&A 313 318 306 305 291 283 283 365 409 451 490 455 471 482 498 518 526 558 564 564
Change (%) 1.48 -3.66 -0.44 -4.67 -2.75 0.25 28.93 11.95 10.37 8.61 -7.29 3.54 2.38 3.38 4.06 1.41 6.12 1.19 -0.16
% of Revenue 63.27 58.85 53.41 50.81 45.02 40.27 37.00 43.74 46.69 48.38 50.25 45.30 42.59 38.76 35.50 34.44 32.05 29.33 25.28 22.71
R&D
Change (%)
% of Revenue
OpEx 1,109 1,104 1,161 1,217 1,160 1,145 1,160 1,273 1,411 1,469 1,563 1,513 1,504 1,511 1,498 1,467 1,559 1,684 2,351 2,482
Change (%) -0.39 5.17 4.82 -4.69 -1.26 1.27 9.74 10.82 4.15 6.39 -3.19 -0.59 0.46 -0.86 -2.08 6.29 7.99 39.59 5.61
% of Revenue 223.91 204.44 202.54 202.84 179.70 163.20 151.48 152.42 161.03 157.47 160.20 150.81 136.13 121.54 106.76 97.48 95.06 88.53 105.25 100.04
Operating Income -613 -564 -588 -617 -515 -444 -394 -438 -535 -536 -587 -510 -399 -268 -95 38 81 218 -117 -1
Change (%) -8.05 4.23 4.97 -16.63 -13.78 -11.13 11.05 22.13 0.28 9.55 -13.21 -21.68 -32.92 -64.59 -140.06 113.30 169.15 -153.75 -99.20
% of Revenue -123.91 -104.44 -102.54 -102.84 -79.70 -63.20 -51.48 -52.42 -61.03 -57.47 -60.20 -50.81 -36.13 -21.54 -6.76 2.52 4.94 11.47 -5.25 -0.04
Interest Expense -50 -60 -62 -64 -66 -64 -64 -64 -63 -53 -44 -33 -23 -22 -20 -19 -19 -18 -19 -19
Change (%) 20.84 3.40 3.42 3.29 -4.05 0.23 0.31 -1.97 -14.95 -17.79 -24.68 -28.83 -6.20 -9.80 -1.97 -1.60 -3.96 1.83 2.11
% of Revenue -10.02 -11.10 -10.81 -10.68 -10.26 -9.05 -8.31 -7.65 -7.15 -5.71 -4.49 -3.29 -2.12 -1.77 -1.41 -1.29 -1.17 -0.97 -0.84 -0.77
Net Income -601 -554 -704 -634 -486 -419 -357 -507 -716 -703 -1,115 -908 -691 -536 17 47 122 235 -248 -58
Change (%) -7.72 27.03 -9.86 -23.38 -13.85 -14.86 42.09 41.37 -1.78 58.53 -18.61 -23.89 -22.42 -103.15 179.91 157.62 93.06 -205.59 -76.67
% of Revenue -121.30 -102.60 -122.77 -105.73 -75.30 -59.66 -46.56 -60.66 -81.76 -75.40 -114.30 -90.46 -62.52 -43.11 1.20 3.14 7.43 12.37 -11.12 -2.34

Source: Capital IQ

Other Listings
MX:SRPT
GB:0L35 US$ 18.52
IT:1SRPT € 15.65
DE:AB3A € 15.67
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista